Project Grant R01CA298372
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Texas at Austin (UT Austin) for $140,328.00. The award period runs from December 17, 2024 to August 15, 2027. The project aims to engineer a stable, high-affinity human methylthioadenosine phosphorylase enzyme that can degrade both adenosine and 5'methylthioadenosine in the tumor microenvironment. This enzyme-mediated depletion of these immunosuppressive...
- The University of Texas MD Anderson Cancer Center was awarded a $616,715 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on August 11, 2025. The grant supports the development of a novel "Microbial-Inspired Immune-Stimulating Antibody-Toxin Conjugate (ATC) for Cancer Immunotherapy". The project aims to engineer an ATC that combines an anti-CD47 antibody with the Listeria monocytogenes toxin LLO, linked via a cleavable linker. This ATC is...
- This $147,486 Project Grant was awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Baylor College of Medicine on December 1, 2025, with a completion date of April 20, 2027. The grant supports a novel immune tolerization strategy called RECON to investigate the trade-offs between oncogene pathogenicity and immunogenicity. The key objective is to uncouple an oncogene's pathogenic potential from its immunogenic properties, enabling the dissection of genetic and...
- This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This $421,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research to investigate how the LIFR-LCN2 pathway in liver cancer restricts the cytotoxic function of CD8+ T cells, leading to immune evasion and resistance to immunotherapy. The central hypothesis is that loss of LIFR upregulates LCN2 in liver cancer, thereby suppressing the abundance and cytotoxic function of CD8+...
- The National Cancer Institute awarded a $148,500 Project Grant under the Cancer Biology Research Program (CFDA 93.396) to the University of North Texas to evaluate the role of extracellular vesicles in modulating the tumor microenvironment, with a focus on their impact on T cell infiltration and suppression in non-small cell lung cancer (NSCLC) and prostate cancer. The project aims to identify specific subpopulations of tumor-derived extracellular vesicles, such as TGN46+ vesicles, that...
- This $399,300 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of an innovative cancer immunotherapy approach at Tiba Biotech LLC, a biotechnology company based in Cambridge, Massachusetts. Specifically, the grant funds the creation of a targeted delivery system that combines enhanced self-amplifying RNA (esRNA) technology and spleen-targeting nanoparticle delivery materials. This platform is designed to stimulate a...
- This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...